Table 1.
Model Variables
| Variable | Best Estimate | Source |
|---|---|---|
| Prevalence of LS in unselected CRC patients | 3.6% | Data from IH's first 18 months of LS screening, and Hampel et al (2008)11 |
| Test costs | Provided by our reference laboratory | |
| Immunohistochemistry | $230 | |
| BRAF V600E | $305 | |
| Methylation of MLH1 promoter | $295 | |
| Proportion of total LS cases by age cohorts | Hampel et al (2005) data set10 | |
| < 50 years | 50.0% | |
| < 60 years | 77.3% | |
| < 70 years | 86.4% | |
| < 80 years | 95.5% | |
| Sensitivity of the screening/testing protocol | 91.5% | Gudgeon et al (2011)9 |
| Cost per CRC case screened | Unpublished internal modeling data | |
| At 100% acceptance for sequencing | $348 | |
| At 50% acceptance for sequencing | $310 |
Abbreviations: CRC, colorectal cancer; IH, Intermountain Healthcare; LS, Lynch syndrome.